Quarterly ResultAug 5, 2026, 04:09 PM
Nyxoah Q2 Revenue €7.7M, up 21%; Secures $110M Financing
AI Summary
Nyxoah SA reported strong financial and operating results for Q2 and H1 2026, driven by U.S. commercial execution. Global net revenue for Q2 2026 reached €7.7 million, a 21% sequential increase, with U.S. net revenue growing 22% sequentially to €5.2 million. The company secured $110 million in financing during Q2, bolstering its cash position to €97.8 million. Operational highlights include significant increases in trained surgeons, activated accounts, and patients under prior authorization, alongside favorable reimbursement developments for its Genio system.
Key Highlights
- Global net revenue for Q2 2026 was €7.7 million, up 21% sequentially.
- U.S. net revenue for Q2 2026 was €5.2 million, up 22% sequentially.
- Secured $110 million in aggregate financing during Q2 2026.
- Cash and cash equivalents totaled €97.8 million as of June 30, 2026.
- 55 new surgeons trained in Q2, bringing total to 262.
- 89 new accounts activated in Q2, totaling 180 active accounts.
- 427 patients actively under prior authorization, a 77% increase.
- Reaffirmed FY2026 revenue guidance of €36 million to €40 million.
Price Impact
More from NYXH